Draft of Russian Clinical Practice Guidelines «Male hypogonadism»

Hypogonadism in males, defined as a decrease in serum testosterone levels in combination with characteristic symptoms and/or signs, can be observed with pathological changes in the testicles and/or pituitary gland, such as Klinefelter’s syndrome, Kallman’s syndrome, as well as in men with metabolic (obesity, diabetes mellitus) or iatrogenic disorders leading to a decrease in androgen production. The draft guidelines cover the extensive range of pathologies that cause hypogonadism development (testosterone deficiency) and focus on its clinical variants, which make up the majority of cases of hypogonadism observed in men. The authors and reviewers are an interdisciplinary group of experts, consisting of endocrinologists, andrologists, urologists - members of the «Russian Association of Endocrinologists» and «Men’s and Reproductive Health» public organizations.

Clinical guidelines contain the most reliable evidence available to experts at the time of writing. Nevertheless, recommendations cannot replace clinical experience, and deciding on the start of treatment, choosing a method of therapy, or a drug should always consider the individual characteristics of a specific patient.

1. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101.

2. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513

3. Agarwal PK, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocr Metab. 2017;21:64-70. doi: https://doi.org/10.4103/2230-8210.196008

4. Beatrice A, Dutta D, Kumar M, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:481-486. doi: https://doi.org/10.2147/DMSO.S50777

5. Ding EL, Song Y, Malik VS, Liu S. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA. 2006;295(11):1288-1299. doi: https://doi.org/10.1001/jama.295.11.1288

6. Rozhivanov RV. Endocrine disorders of sexual function in men. In: Dedov II, Mel’nochenko GA, editors. Rational pharmacotherapy of diseases of the endocrine system and metabolic disorders. 2nd ed. Moscow; 2013. P. 754-775. (In Russ.).

7. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi: https://doi.org/10.1210/jc.2016-3580

8. Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: https://doi.org/10.1210/jc.2006-0401

9. Tan WS, Ng CJ, Khoo E-M, et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male. 2011;14(4):231-236. doi: https://doi.org/10.3109/13685538.2011.597463

10. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is Low Testosterone Concentration a Risk Factor for Metabolic Syndrome in Healthy Middle-aged Men? Urology. 2013;82(4):814-819. doi: https://doi.org/10.1016/j.urology.2013.06.023

11. Ho C-H, Jaw F-S, Wu C-C, et al. The Prevalence and the Risk Factors of Testosterone Deficiency in Newly Diagnosed and Previously Known Type 2 Diabetic Men. J Sex Med. 2015;12(2):389-397. doi: https://doi.org/10.1111/jsm.12777

12. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. doi: https://doi.org/10.3275/8061

13. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. European Journal of Endocrinology. 2011;166(1):77-85. doi: https://doi.org/10.1530/eje-11-0743

14. Reddy RG, Aung T, Karavitaki N, Wass JAH. Opioid induced hypogonadism. BMJ. 2010;341(aug31 1):c4462-c4462. doi: https://doi.org/10.1136/bmj.c4462

15. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221-238. doi: https://doi.org/10.1016/j.beem.2010.08.013

16. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(3):14-22.

17. Bhasin S, Pencina M, Jasuja GK, et al. Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi: https://doi.org/10.1210/jc.2010-3012

18. Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods. Steroids. 2009;74(6):498-503. doi: https://doi.org/10.1016/j.steroids.2009.01.004

19. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. doi: https://doi.org/10.1016/S2213-8587(20)30367-3

20. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis. Ann Intern Med. 2009;151:650-661. doi: https://doi.org/10.1059/0003-4819-151-9-200911030-00150

21. Rozhivanov RV, Kurbatov DG, Kravtsova NS. Differential and diagnostic, predictive and therapeutic value of test with clomifene in men with a Hypogonadizm. Problems of Endocrinology. 2016;62(1):35-37. (In Russ.). doi: https://doi.org/10.14341/probl201662135-37

22. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005;28(3):28-31.

23. Bremner AP, Feddema P, Leedman PJ, et al. Age-Related Changes in Thyroid Function: A Longitudinal Study of a Community-Based Cohort. J Clin Endocr Metab. 2012;97(5):1554-1562. doi: https://doi.org/10.1210/jc.2011-3020

24. Rozhivanov RV. Effective therapy and errors in treatment of endocrine disorders in andrology. In: Dedov II, Melnichenko GA, editors. Endocrinology. Pharmacotherapy without errors. Moscow; 2013. P. 615-625. (in Russ.).

25. Rozhivanov RV, Shurdumova BO, Parfenova NS, Savel’eva LV. Kompleksnyy podkhod k lecheniyu ozhireniyai metabolicheskogo sindroma u muzhchin. Obesity and metabolism. 2009;6(4):38-41. (In Russ.). doi: https://doi.org/10.14341/2071-8713-4877

26. Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133. doi: https://doi.org/10.1016/j.mce.2015.06.031

27. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1

28. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Endocrinol Metab. 2006;91(6):2011-2016. doi: https://doi.org/10.1210/jc.2006-0036

29. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280-293. doi: https://doi.org/10.1111/j.1365-2265.2005.02339.x

30. Basaria S, Lakshman KM. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: https://doi.org/10.2147/CIA.S4466

31. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575

32. Calof OM, Singh AB, Lee ML, et al. Adverse Events Associated With Testosterone Replacement in Middle-Aged and Older Men: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Journals Gerontol Ser A Biol Sci Med Sci. 2005;60(11):1451-1457. doi: https://doi.org/10.1093/gerona/60.11.1451

33. Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;363(2):109-122. doi: https://doi.org/10.1056/NEJMoa1000485

34. Johansen Taber KA, Morisy LR, Osbahr AJ 3rd, et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol Rep. 2010;24(5):1115-1120. doi: https://doi.org/10.3892/or_00000962

35. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: A systematic review. Int J Impot Res. 2009;21(1):9-23. doi: https://doi.org/10.1038/ijir.2008.31

36. Marks LS, Mazer NA, Mostaghel E, et al. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. JAMA. 2006;296(19):2351. doi: https://doi.org/10.1001/jama.296.19.2351

37. Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96(3):263-265. doi: https://doi.org/10.1007/s10549-005-9074-y

38. Ohlander SJ, Lindgren MC, Lipshultz LI. Testosterone and Male Infertility. Urol Clin North Am. 2016;43(2):195-202. doi: https://doi.org/10.1016/j.ucl.2016.01.006

39. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: https://doi.org/10.1517/14740338.2014.950653

40. Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500-1511. doi: https://doi.org/10.2174/138161211796197160

41. Moon DG, Park MG, Lee SW, et al. The Efficacy and Safety of Testosterone Undecanoate (Nebido®) in Testosterone Deficiency Syndrome in Korean: A Multicenter Prospective Study. The Journal of Sexual Medicine. 2010;7(6):2253-2260. doi: https://doi.org/10.1111/j.1743-6109.2010.01765.x

42. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology. 2011;165(5):675-685. doi: https://doi.org/10.1530/eje-11-0221

43. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi: https://doi.org/10.1111/j.1365-2141.2005.05535.x

44. Rozhivanov RV, Kurbatov DG. Hematological and urological aspects of the safety of androgen substitution therapy using long-acting testosterone undecanoate in patients with hypogonadism. Problems of Endocrinology. 2009;55(6):31-35. (In Russ.). doi: https://doi.org/10.14341/probl200955631-35

45. Kardoust Parizi M, Abufaraj M, Fajkovic H, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol Semin Orig Investig. 2019;37(10):637-646. doi: https://doi.org/10.1016/j.urolonc.2019.06.007

46. Morgentaler A, Morales A. Should Hypogonadal Men With Prostate Cancer Receive Testosterone? J Urol. 2010;184(4):1257-1260. doi: https://doi.org/10.1016/j.juro.2010.07.010

47. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920-922. doi: https://doi.org/10.1097/01.ju.0000136269.10161.32

48. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536-541. doi: https://doi.org/10.1002/cncr.22438